bioRxiv Science⌕ Search

Biology subjects

Kelley, Z.

Publications and source records attributed to Kelley, Z..

2 recordsLinked to original sources

Crosslinked CXCR4 Signals Decreased Motility and Increased Adhesion of T Cells

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive cancer known for its ability to evade immune surveillance, primarily through mechanisms that prevent T cell infiltration. While the coating of cancer cells with the chemokine, CXCL12, is required for the exclusion of T cells, the precise molecular mechanisms behind the failure of T cell migration into the tumor remain unclear. In this study, we identify a potential mechanism by demonstrating that crosslinking CXCR4 is associated with decreased motility of T cells secondary to their adhesion to fibronectin. Using human lymphoblastoid T cells and primary human T cells, we show that polymeric CXCL12-induced crosslinked CXCR4 triggers the non-G i-dependent pathway of tyrosine phosphorylation of FAK-related proline-rich tyrosine kinase 2 (PTK2B) in T cells. This response is necessary for the decreased motility and increased adhesion of T cells. We also find that the downstream cellular reactions of this pathway is secondary to CXCR4-crosslinking and require the integrin subunit, 4, and TNF stimulation of TNFRSF1B. These findings provide insights into the mechanisms mediating the exclusion of T cells from nests of PDA cells and further support therapeutic strategies aimed at blocking the interaction of CXCR4 on T cells with the CXCL12-coating of PDA cells.

immunology↗

Senolytics Restore Hematopoietic Stem Cells Function in Sickle Cell Disease

Sickle Cell Disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, possibly due to pathological stress on bone marrow. To investigate this further, we interrogated mice and individuals with SCD and observed extended cell cycle times, oxidative stress, DNA damage, senescence, and dysregulation of molecular programs associated with these processes in bone marrow hematopoietic stem and progenitor cells (HSPCs). Human SCD HSPCs displayed poor hematopoietic potential ex vivo. SCD mice displayed a dramatic loss of transplantable bone marrow HSPCs, which was reversed upon treatment of SCD mice with the senolytic agent, ABT-263 (navitoclax). Thus, senolytics restore bone marrow function during SCD in mice and represent a novel strategy to improve bone marrow health in individuals with SCD and improve the safety of potentially curative gene therapies that utilize autologous HSPCs from individuals with SCD.

cell biology↗